A2A Pharmaceuticals, Inc.'s Form 4 filing
Biomea Fusion, Inc. (BMEA) · filed Jul 25, 2022
- Accession no.
- 0001859061-22-000001
- Filed
- Jul 25, 2022
- Trade date
- Jul 21, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $388.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| A2A Pharmaceuticals, Inc.CIK 0001859061 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2022 | Common Stock | SSaleDisposed | −34,658 | $11.21 | −$388,516.18 | 4,330,684 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
A total of 34,658 shares were sold at an average price of 11.21 in multiple transactions ranging in price from 11.00 to 11.76. Additional details of the individual transactions are available upon request.